Navigation Links
aTyr Pharma Announces Publication of a Rare Muscle Disease Associated with Regulation of a Potential Physiocrine
Date:7/14/2014

SAN DIEGO, July 14, 2014 /PRNewswire/ -- aTyr Pharma, an innovative rare disease therapeutics enterprise announced today, the scientific publication of a splice variant of a tRNA synthetase in association with a rare muscle disease.  This article, published in the Journal of Biological Chemistry, demonstrated novel findings relative to Physiocrine proteins, that include extracellular functions derived from the tRNA synthetase gene family.  These data further highlight the potential role of Physiocrine splice variants in muscle physiology.  The data is consistent with the discovered splice variant being a target of auto-antibodies in a rare muscle disease.

"This is an important milestone in our journey towards understanding the role that physiocrines, like those described in this paper, play in regulating tissue homeostasis in normal tissues and in diseased states," said John Mendlein, Ph.D., CEO and executive chairman of aTyr Pharma. 

About Physiocrines
Among their various homeostatic functions, some Physiocrines act as extracellular signaling molecules to orchestrate immuno-homeostasis in response to stress and other physiological changes. Physiocrines comprise naturally occurring proteins derived from tRNA synthetases that play fundamental roles in the function of human physiology and restoring pathophysiological states to a healthier state. aTyr is currently focused on Physiocrines that act as endogenous modulators of our immune and regenerative systems. Physiocrines offer the opportunity for modulating biological pathways through newly discovered naturally occurring mechanisms, many of which may provide multiple therapeutic advantages, including improved efficacy and reduced side effect profiles compared to many existing therapeutics.

About aTyr Pharma
aTyr Pharma is developing  a pipeline of therapeutic products based on Physiocrine biology. To protect these products aTyr built a dominant intellectual property estate comprising over 200 patent applications and patents. aTyr's key programs are currently focused on rare disorders where the immune system is imbalanced. These diseases are serious potentially life threatening autoimmune conditions, for which there are currently no effective, safe, long term treatments. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Partners. For more information, please visit http://www.atyrpharma.com.

Media Contact:
Holly Chrzanowski
hchrzanowski@atyrpharma.com
+1.619.742.4452

Logo - http://photos.prnewswire.com/prnh/20120809/MM55538LOGO


'/>"/>
SOURCE aTyr Pharma
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
6. Academy of Managed Care Pharmacy (AMCP) Installs 2012-2013 Board of Directors
7. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
8. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
9. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
10. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
11. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... 28, 2017 Persistence Market Research in ... Debridement Product Market 2016-2024," offers insights into developments ... North America that are significantly ... the overall market performance has been taken into ... focuses on developing different products to retain market ...
(Date:2/28/2017)... Intraocular Lens Market: Overview Read the full report: ... ... / opaqueness of the natural lens of the eye, which ... permanent loss of vision. Intraocular Lens is a type of ... Cataract is considered as one of the most common eye ...
(Date:2/28/2017)... , Feb. 28, 2017 The global gynecology surgical ... 2021 from USD 1.73 billion in 2016, at a CAGR ... ... http://www.reportlinker.com/p04734938-summary/view-report.html Major factors contributing to the growth ... diseases, increasing awareness on gynecological diseases, and rising government investments ...
Breaking Medicine Technology:
(Date:3/1/2017)... ... 01, 2017 , ... Financial Recovery Group, Inc. (FRG), is proud to announce ... Nashville, Tenn. The company also is offering a special discount for those who attend ... year, brings together the brightest minds in the healthcare industry to share information on ...
(Date:3/1/2017)... ... March 01, 2017 , ... Look for a new collection of ... and Drift Roses. Star Roses and Plants is launching their new Bushel and ... Bushel and Berry Collection makes growing fresh fruit simple with a variety of easy-to-grow, ...
(Date:3/1/2017)... , ... March 01, 2017 , ... On January 27, ... Firm, filed a civil sex abuse lawsuit in the Circuit Court of Kanawha County, ... have only been identified by their initials. See L.B. and T.B. v. Seventh-Day Adventist ...
(Date:3/1/2017)... , ... March 01, 2017 , ... Award-winning medical group ... 25 medical mission trips in underdeveloped nations, averaging more than one trip per year ... article on the website features the details of his charitable work. Char ...
(Date:3/1/2017)... ... 2017 , ... NYC based Integrated practice Living Well Medical, a long time ... of Orthopaedic Surgeon Dr. Donald E. Heitman. Dr. Heitman is a native ... Bachelor of Science degree in biology. He then obtained his medical degree from New ...
Breaking Medicine News(10 mins):